Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05690581RecruitingPhase 1
CM369 for advanced cancers with special immune marker in tumors
This Phase 1 study tests how safe and tolerable CM369 is in people with advanced solid tumors or blood cancers. It also looks at how the drug behaves in the body and whether it can help shrink or control cancer, especially when a tumor marker called CCR8 is present.
Guangzhou, GuangdongAges 18–75 - NCT07541534RecruitingPhase 1
HLX316 immunotherapy for advanced solid tumors
This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.
ChongqingAges 18 years+ - NCT07539285RecruitingPhase 1
HDM2024 treatment for advanced solid tumors
This study tests a new cancer drug called HDM2024 in people with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have stopped responding to standard treatments. The drug is designed to target specific proteins called EGFR and HER3 on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07532018RecruitingPhase 1
Study of DXP-106 for advanced solid tumors
This trial tests an investigational drug called DXP-106 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the cancer.
Harbin, HeilongjiangAges 18–80 - NCT07529002Recruiting
New PET scan imaging test for solid tumors
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
Beijing, Beijing MunicipalityAges 15–70 - NCT05417321RecruitingPhase 1/Phase 2
Test of HB0036 for advanced cancers that ran out of options
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Lafayette, IndianaAges 18 years+ - NCT07524348RecruitingPhase 1
Safety Study of E303 Drug in Advanced Solid Tumors
This early-stage trial tests whether a new drug called E303 is safe for patients with advanced solid cancers (tumors that have spread or returned). Researchers want to find the right dose and watch for side effects.
Scottsdale, ArizonaAges 18 years+ - NCT07508761RecruitingPhase 1/Phase 2
IPG7236 with Toripalimab for advanced solid tumors
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
Shanghai, PuDongXinQuAges 18 years+ - NCT07505069RecruitingEarly Phase 1
PET imaging study for people with solid tumors
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
Wuxi, JiangsuAges 18–75 - NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06657690RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after immunotherapy
This trial tests a combination of two drugs, irinotecan liposome and S-1, for people with a type of nose and throat cancer that has spread or come back after treatment with immunotherapy (PD-1/L1 inhibitors). The goal is to see if this new combination can help when standard treatments have stopped working.
Zhuhai, GuangzhouAges 18–70 - NCT06472713RecruitingPhase 2
Liposomal mitoxantrone with immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Zhuhai, GuangdongAges 18–70 - NCT06640725RecruitingPhase 2
TPEx chemo with maintenance immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy drugs (TPEx) followed by two immunotherapy drugs (avelumab and cetuximab) as a first treatment for head and neck cancer that has spread or come back. It is for people whose tumors show a protein called PD-L1 and who have not had chemotherapy for advanced disease before.
Vandœuvre-lès-NancyAges 18–74 - NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75 - NCT07477743RecruitingPhase 1
Study of a new drug combo for advanced solid tumors
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
BeijingAges 18–75 - NCT07480733RecruitingPhase 2
Study of two drugs for advanced solid tumors
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06772415RecruitingPhase 1
Study of GenSci122 for advanced solid tumors
This trial tests an experimental pill called GenSci122 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07467629RecruitingPhase 1
Study of QLS5212 for people with advanced solid tumors
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
TaiyuanAges 18 years+ - NCT07466160RecruitingPhase 1/Phase 2
Study of two experimental drugs for advanced solid tumors
This trial tests a new combination of two investigational drugs, 7MW3711 and JS207, for people with advanced solid tumors that no longer respond to standard treatments. It aims to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05341557RecruitingPhase 1
First-in-human drug study for advanced cancers and lymphoma
This Phase 1 trial tests BPI-371153, a new treatment, in people with advanced solid tumors or relapsed or refractory lymphoma whose cancer has returned or progressed after standard care. The goal is to find a safe dose and learn whether it can shrink tumors or help control disease.
Chaoyang, Beijing MunicipalityAges 18 years+ - NCT05789602RecruitingPhase 1
Study drug for advanced solid tumors in adults
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07455734RecruitingPhase 1/Phase 2
Testing BNT3214 for advanced solid tumors
This trial tests an experimental drug, BNT3214, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if BNT3214 is safe and helps shrink tumors.
ClaytonAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT07446153RecruitingPhase 1/Phase 2
HRS-8364 for advanced solid tumors
This trial tests a new medicine, HRS-8364, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if the drug can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–75
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.